GeneDx Holdings (WGS) Gains from Investment Securities (2020 - 2026)

GeneDx Holdings (WGS) has reported Gains from Investment Securities for 7 consecutive years, with -$2.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 330.91% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$2.4 million (down 129.11% YoY), while the FY2025 annual figure was $1.2 million, down 90.99% from the prior year.
• Gains from Investment Securities slipped to -$2.5 million in Q1 2026 per WGS's latest filing, from -$1.1 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $6.1 million in Q1 2024 and bottomed at -$28.2 million in Q2 2022.
• Historically, Gains from Investment Securities has averaged -$3.5 million across 5 years, with a median of -$590000.0 in 2023.
• Annual changes were most pronounced in 2024 — Gains from Investment Securities soared 507.41% — and 2026, when it plunged 330.91%.
• GeneDx Holdings' Gains from Investment Securities stood at -$15.9 million in 2022, then jumped by 96.94% to -$486000.0 in 2023, then jumped by 507.41% to $2.0 million in 2024, then plunged by 156.36% to -$1.1 million in 2025, then plunged by 127.6% to -$2.5 million in 2026.
• Business Quant data shows WGS's Gains from Investment Securities at -$2.5 million in Q1 2026, -$1.1 million in Q4 2025, and $3.4 million in Q3 2025.